{"filing":{"accession_number":"0001438133-26-000124","cik":"0001438133","ticker":"TNDM","company_name":"TANDEM DIABETES CARE INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tndm-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438133/000143813326000124/tndm-20260806.htm"},"events":[{"id":25754,"run_id":23374,"accession_number":"0001438133-26-000124","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Tandem Diabetes Care issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 sales of $254.6 million, gross margin of 57%, operating loss of $13.8 million, and net loss of $21.2 million, along with 2026 full-year financial guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and trajectory.","company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26666,"accession_number":"0001438133-26-000124","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Tandem Diabetes Care issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 sales of $254.6 million, gross margin of 57%, operating loss of $13.8 million, and net loss of $21.2 million, along with 2026 full-year financial guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:22.273770+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26666,"accession_number":"0001438133-26-000124","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Tandem Diabetes Care issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 sales of $254.6 million, gross margin of 57%, operating loss of $13.8 million, and net loss of $21.2 million, along with 2026 full-year financial guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:22.273770+00:00","company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","filing_date":"2026-08-06"}]}